These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18790022)

  • 1. Challenges in molecular imaging of Parkinson's disease: a brief overview.
    Kassiou M; Banati R; Holsinger RM; Meikle S
    Brain Res Bull; 2009 Feb; 78(2-3):105-8. PubMed ID: 18790022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional imaging of non-motor signs in Parkinson's disease.
    Ballanger B; Poisson A; Broussolle E; Thobois S
    J Neurol Sci; 2012 Apr; 315(1-2):9-14. PubMed ID: 22154188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroimaging in Parkinson's disease].
    Hilker R; Steinmetz H
    Nervenarzt; 2010 Oct; 81(10):1159. PubMed ID: 20857277
    [No Abstract]   [Full Text] [Related]  

  • 4. Imaging cognitive and behavioral symptoms in Parkinson's disease.
    Antonelli F; Ray N; Strafella AP
    Expert Rev Neurother; 2010 Dec; 10(12):1827-38. PubMed ID: 21091314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of PET in Parkinson's disease.
    Shinotoh H; Calne DB
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine A(2A) receptor antagonists as Positron Emission Tomography (PET) tracers.
    Khanapur S; Waarde Av; Ishiwata K; Leenders KL; Dierckx RA; Elsinga PH
    Curr Med Chem; 2014; 21(3):312-28. PubMed ID: 24059232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing new molecular imaging probes for PET.
    Serdons K; Verbruggen A; Bormans GM
    Methods; 2009 Jun; 48(2):104-11. PubMed ID: 19318126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Positron emission tomography. A new measurement method for imaging of regional and biochemical parameters].
    Bolwig TG; Haunsø S; Hove JD; Hesse B; Højgaard L; Jensen M; Paulson OB; Svendsen JH; Sørensen SS
    Ugeskr Laeger; 1994 Oct; 156(43):6341-7. PubMed ID: 7810006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT.
    Ceballos-Baumann AO
    J Neurol; 2003 Feb; 250 Suppl 1():I15-23. PubMed ID: 12761630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular imaging in Parkinson's disease].
    Arahata Y; Kato T; Ito K
    Nihon Rinsho; 2007 Feb; 65(2):327-31. PubMed ID: 17302279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional brain imaging of movement disorders.
    Eidelberg D; Edwards C
    Neurol Res; 2000 Apr; 22(3):305-12. PubMed ID: 10769825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography studies in parkinsonism.
    Eidelberg D
    Neurol Clin; 1992 May; 10(2):421-33. PubMed ID: 1584183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of brain MRI and 18F-FDG PET in the differentiation of Parkinsonian-type multiple system atrophy from Parkinson's disease.
    Kwon KY; Choi CG; Kim JS; Lee MC; Chung SJ
    Eur J Neurol; 2008 Oct; 15(10):1043-9. PubMed ID: 18717730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.
    Au WL; Adams JR; Troiano AR; Stoessl AJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):24-33. PubMed ID: 15790527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of brain MRI and 18F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease.
    Kwon KY; Choi CG; Kim JS; Lee MC; Chung SJ
    Mov Disord; 2007 Dec; 22(16):2352-8. PubMed ID: 17894342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease.
    Borghammer P; Cumming P; Aanerud J; Gjedde A
    Neuroimage; 2009 Apr; 45(2):249-57. PubMed ID: 18718541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Eckert T; Tang C; Eidelberg D
    Lancet Neurol; 2007 Oct; 6(10):926-32. PubMed ID: 17884682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of Parkinson's disease].
    Arias-Rodríguez M; Morís-De la Tassa G
    Rev Neurol; 2009 Jan; 48 Suppl 1():S21-5. PubMed ID: 19222011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
    Morrish PK
    Mov Disord; 2003 Oct; 18 Suppl 7():S63-70. PubMed ID: 14531048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Parkinson's disease biomarkers.
    Prakash KM; Tan EK
    Expert Rev Neurother; 2010 Dec; 10(12):1811-25. PubMed ID: 21091313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.